The 4-dose KwikPen device supports weight reduction in patients with obesity or overweight with weight-related conditions.
The FDA has approved a label expansion for once-weekly tirzepatide for adults with overweight and obesity, allowing the medication to be used with a pen that is equipped with four doses of the drug, ...
Eli Lilly and Company (NYSE: LLY) today announced the U.S. Food and Drug Administration (FDA) approved a label expansion for ...
Eli Lilly has rolled out a multi-dose KwikPen version of tirzepatide, marketed as Zepbound, for chronic weight management—signaling a packaging update for one of the obesity market’s fastest-expanding ...
The FDA has approved a new four-dose, single-patient-use KwikPen for Zepbound (tirzepatide), giving patients a full month of treatment in one device.
Patients who pay cash can get the multi-dose KwikPen device on LillyDirect, with prices starting at $299 for the lowest dose.
Consolidation of four doses may lower secondary packaging complexity and improve fill-finish throughput predictability, although Lilly has not quantified manufacturing efficiency gains. Multi-dose use ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results